- Conditions
- Burns, Second Degree Burn, Wounds and Injuries
- Interventions
- Drug: 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- John Elfar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 58
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Congenital Myasthenic Syndrome
- Interventions
- 3,4-Diaminopyridine
- Drug
- Lead sponsor
- Ricardo Maselli
- Other
- Eligibility
- 3 Months to 75 Years
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Spinal Muscular Atrophy
- Interventions
- 4-aminopyridine, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Parkinson's Disease
- Interventions
- Ampyra first, then Placebo, placebo first, then Ampyra
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Placebo, Dalfampridine
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Botulism, Iatrogenic Botulism
- Interventions
- Amifampridine
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Ischemic Stroke
- Interventions
- placebo/dalfampridine-ER, dalfampridine-ER/placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • La Jolla, California • Newport Beach, California + 17 more
- Conditions
- Non Arteritic Ischemic Optic Neuropathy
- Interventions
- dalfampridine, Placebo
- Drug
- Lead sponsor
- Neuro-Ophthalmologic Associates, PC
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Post-ischemic Stroke
- Interventions
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 62
- States / cities
- Gilbert, Arizona • Berkeley, California • Carlsbad, California + 54 more
- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- amifampridine phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Spinal Cord Injury, Muscle Spasticity
- Interventions
- Fampridine-SR, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Multiple Sclerosis
- Interventions
- Dalfampridine-ER 5mg, Dalfampridine-ER 10mg, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 70
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 59 more
- Conditions
- Multiple Sclerosis, Fatigue
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Sclerosis
- Interventions
- dalfampridine ER, placebo
- Drug
- Lead sponsor
- Brown, Theodore R., M.D., MPH
- Individual
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Multiple Sclerosis
- Interventions
- Dalfampridine 10 MG [Ampyra], Physical therapy, Dalfampridine plus physical therapy
- Drug · Behavioral · Other
- Lead sponsor
- MGH Institute of Health Professions
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- SCI - Spinal Cord Injury
- Interventions
- Dalfampridine, Placebo, STDP stimulation, Exercise training
- Drug · Other · Behavioral
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Vern C. Juel, M.D.
- Other
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 31 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Mount Sinai Rehabilitation Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Cerebral Palsy (CP)
- Interventions
- dalfampridine-ER 10mg, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Downey, California • Los Angeles, California + 8 more
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Imatinib, Fampridine
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- La Jolla, California